This week, the U.S. Food and Drug Administration (FDA) removed 2 of 3 approved indications for the semi-synthetic macrolide antibiotic telithromycin (Ketek, manufactured by sanofi-aventis). Ketek loses its indication for (1) acute bacterial sinusitis and (2) acute bacterial exacerbations of chronic bronchitis, often abbreviated as “ABECB”. Ketek remains approved for community acquired pneumonia of mild [...]
Read the full article →
Some special interest groups are very critical of financial conflicts of interests between businesses (namely, pharmaceutical industry) and doctors and scientists. I’ve seen and worked on both sides. I think it’s very important to educate doctors and scientists on all aspects of medicine – the scientific, business, and sociopolitical aspects. Don’t like the purported influence [...]
Read the full article →